Does Rallies show Form 4 insider transactions for NEOG?

Yes. Rallies tracks NEOG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NEOG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NEOG. It does not provide personalized investment advice.

NEOG (Neogen Corp) Stock Analysis - Insider Trades

Neogen Corp (NEOG) is a publicly traded Healthcare sector company. As of May 21, 2026, NEOG trades at $8.83 with a market cap of $1.86B and a P/E ratio of -3.07. NEOG moved +5.75% today. Year to date, NEOG is +21.63%; over the trailing twelve months it is +42.42%. Its 52-week range spans $3.87 to $17.18. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces NEOG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NEOG stock inside the company?

Recent NEOG insider activity includes Nassif Mikheal bought 23, Nassif Mikheal bought 24, Nassif Mikheal bought 25, Nassif Mikheal bought 137, and Nassif Mikheal bought 177. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NEOG Key Metrics

Key financial metrics for NEOG
Metric	Value
Price	$8.83
Market Cap	$1.86B
P/E Ratio	-3.07
EPS	$-2.80
Dividend Yield	0.00%
52-Week High	$17.18
52-Week Low	$3.87
Volume	3
Avg Volume	0
Revenue (TTM)	$870.54M
Net Income	$-608.84M
Gross Margin	45.20%

Recent NEOG Insider Trades

Nassif Mikheal bought 23 (~$251.62) on Feb 17, 2026.
Nassif Mikheal bought 24 (~$239.993) on Feb 2, 2026.
Nassif Mikheal bought 25 (~$246.375) on Jan 26, 2026.
Nassif Mikheal bought 137 (~$1.28K) on Jan 16, 2026.
Nassif Mikheal bought 177 (~$1.11K) on Nov 3, 2025.

Latest NEOG News

Neogen Q3 Revenue Falls 4.4% to $211.2M; Food Safety Up 2.6% — Apr 9, 2026
Neogen Sees Q3 EPS Drop to $0.04, Revenue Down 7.5%, Genomics Sale Boosts Shares — Apr 7, 2026
Neogen Sells Genomics Business with $90M Sales to Zoetis for $160M — Mar 2, 2026
Neogen’s Q4 Revenue Hits $224.7M, Beats Forecast by 7.2% — Feb 25, 2026
Neogen Recalls HYCOAT Vials After Microbial Contamination; Q2 Revenue Falls 2.8% — Feb 23, 2026

NEOG Analyst Consensus

2 analysts cover NEOG: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about NEOG

Who is trading NEOG stock inside the company?: Recent NEOG insider activity includes Nassif Mikheal bought 23, Nassif Mikheal bought 24, Nassif Mikheal bought 25, Nassif Mikheal bought 137, and Nassif Mikheal bought 177. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NEOG?: Yes. Rallies tracks NEOG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NEOG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NEOG. It does not provide personalized investment advice.